SELECT PUBLICATIONS

Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract

Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;[Epub ahead of print]. Abstract

Cianfrocca M, Gradishar WJ. Controversies in the therapy of early stage breast cancer. Oncologist 2005;10(10):766-79. Abstract

Crown J et al. Docetaxel (T) given either concurrently or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa). Comparison with non-taxane combination chemotherapy. First results of the BIG 2-98 Trial at 5 years median follow-up. Proc ASCO 2006;Abstract LBA519. Abstract

Harlan LC et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006;24(6):872-7. Abstract

Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.

Knoop A et al. TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). Proc ASCO 2006; Abstract 532.

Kummel S et al. Randomised trial: Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 2006;94(9):1237-44. Abstract

Mamounas EP et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23(16):3686-96. Abstract

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Martin M et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: Interim efficacy analysis of GEICAM 9906 Trial. San Antonio Breast Cancer Symposium 2005;Abstract 39.

Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract

Roche H et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 27.

Trudeau M et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005;6(11):886-98. Abstract